{"id":"belatacept-mi-more-intensive","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including CMV, BK virus)"},{"rate":null,"effect":"Malignancy"},{"rate":null,"effect":"Acute rejection"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Belatacept is a fusion protein (CTLA4-Ig) that blocks the CD28 costimulatory pathway by binding to CD80 and CD86 on antigen-presenting cells. This prevents the second signal required for full T-cell activation, thereby suppressing immune responses. The 'more intensive' formulation refers to a higher-dose regimen designed to provide enhanced immunosuppression in transplant recipients.","oneSentence":"Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:59.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)"}]},"trialDetails":[{"nctId":"NCT00114777","phase":"PHASE3","title":"Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Renal Transplantation","enrollment":595},{"nctId":"NCT00256750","phase":"PHASE3","title":"Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-03","conditions":"Kidney Transplantation, Chronic Kidney Failure","enrollment":738},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00555321","phase":"PHASE2","title":"Belatacept in Liver Transplant Recipients","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Immunosuppression in Solid Organ Transplant","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Belatacept MI (more intensive)","genericName":"Belatacept MI (more intensive)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation. Used for Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}